## Maryland Board of Pharmacy Public Board Meeting

## Agenda April 17, 2024

Name	Title	Present	Absent
Evans, K.	Commissioner		
Fink, K.	Commissioner		
Geigher, P.	Commissioner/Treasurer		
Hardesty, J.	Commissioner		
Leikach, N.	Commissioner/President		
Morgan, K.	Commissioner		
Oliver, B.	Commissioner		
Oriafo, A.	Commissioner		
Patel, A.	Commissioner		
Robinson, D.	Commissioner/Pharmacy Technician		
Rusinko, K.	Commissioner/Secretary		
Slagle, K.	Commissioner		
Vázquez, J.	Commissioner		
Bethman, L.	Board Counsel		
Felter, B.	Board Counsel		
Speights-Napata, D.	Executive Director		
Partin, J.	Network Specialist		
James, D.	Licensing Manager		
Leak, T.	Compliance Director		
Vacant	Legislative Liaison		
Chew, C.	Enforcement Compliance Auditor		

Subject Responsi	Discussion Discussion	Action Due Date (Assigned To)
------------------	-----------------------	----------------------------------

I. Executive Committee Report(s)	A.) N. Leikach, Board President	Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.  1. Call to Order  2. Sign-in Introduction and of meeting attendees – (Please indicate on sign-in sheet if you are requesting CE Units for attendance)  3. Distribution of Agenda and packet materials	
	B.) K. Rusinko, Secretary	4. Review and approve March 2024 Public Meeting Minutes	
II. A. Executive Director Report	D. Speights- Napata Executive Director	1. Meeting Update 2. Staff Update	
B. New Business	N. Leikach, Board President		
C. Operations	J. Partin, Network Specialist	1. Procurement and Budget Updates a. Financials –  2. Management Information Systems (MIS) Unit Updates	
D. Licensing	K. Rusinko	1. Unit Updates 2. Monthly Statistics	

Subject Responsible Party	Discussion	Action Due Date (Assigned To)
---------------------------	------------	----------------------------------

			License Type	New	Renewed	Reinstated	Total
			Distributor	15	0	0	1,507
			Pharmacy	6	230	0	2,093
			Pharmacist	38	482	4	12,704
			Vaccination	19	200	0	5,324
			Pharmacy	2	0	0	34
			Intern -				
			Graduate				
			Pharmacy	5	5	0	396
			Intern –				
			Student				
			Pharmacy	131	313	14	10,381
			Technician				
			Pharmacy	2	0	0	39
			Technician-				
			Student				
			TOTAL	218	1,230	18	32,478
E. Compliance	T. Leak,	1.	<b>Unit Updates</b>				
	Compliance	2.	<b>Monthly Stati</b>	stics			
	Director						
		Com	plaints & Inv	esugauons	•		
		New	Complaints -	63			
			Refusal to l	F111 - 6			

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		Inspection Issues- 39	
		Medication Error - 1	
		• Customer Service- 6	
		• Licensing Issues- 2	
		• Employee Pilferage- 2	
		Out-of-State Disciplinary Actions -6     Missell access Advance Containing 1	
		Miscellaneous: Adverse Customer Reaction -1	
		Resolved- 43	
		Actions within Goal- 38/43	
		Formal (Final) Disciplinary actions taken- 3	
		Summary Actions Taken- 1	
		Average Days to Complete- 55	
		Regulatory Inspections:	
		Total - 120	
		Annual Inspections - 110	
		• Chain - 48	
		• Independent - 24	
		• Sterile Compounding - 9	
		• Repository - 16	
		• Comprehensive Care - 0	
		Hospital - 6	
		<ul> <li>Supplemental Assisted Living - 4</li> </ul>	
		• Follow up - 0	
		• Distributor - 3	
		• Attempted- 0	
		On animas/Dama dala/Dala sations A	
		Openings/Remodels/Relocations - 4	
		Closing Inspections - 6 Change of Ownership - 0	
		Pending Opening – 0	
		Pending Closing - 1	
1		1 thung crosing - 1	

	Responsible		Action Due Date
Subject	Party	Discussion	(Assigned To)
			-

	1		
F. Legislation & Regulations	Legislative Liaison	Legislation	
		NONE	
		Regulations	
		COMAR 10.34.42 Review of proposed responses to comments submitted regarding (Nicotine Replacement Therapy)	
		Proposed COMAR 10.34.34.02, .03, .06, and .09 (expanded pharmacy technician duties). The anticipated date of publication is April 5, 2024.	
III. Committee Reports	K, Evans, Chair	Practice of Pharmacy Questions	
_		NONE	
A. Practice Committee			
		Drug Therapy Management	
		Pharmacy: LifeBridge Pharmacists: Mingxiang Wang, Michelle Mays, Veena Bettegowda, and Patricia Erin Kokoski (Maryam D'Alberto pending approval) Protocol: Clinic Management, Warfarin Management, Anticoagulation Reversal and Management of Bleeding, Perioperative Warfarin Interruption and Bridging with Parenteral Anticoagulants, and Direct Oral Anticoagulant Management.	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		Pharmacy: Johns Hopkins Pharmacists: Pharmacist: Katharine Russo Protocols: Hypertension, Diabetes, Smoking Cessation, Cardiovascular Risk Reduction, and Management of Acid Suppressing Pharmacotherapy.  Pharmacist: Aklil Hiruy Protocols: Renal Dose Adjustment, Therapeutic Drug Monitoring, and Antithrombotics  Pharmacist: Katie Dircksen Protocols: Renal Dose Adjustment, Therapeutic Drug Monitoring, Antithrombotics, and Management of Acid Suppressing Pharmacotherapy Commissioners Rusinko and Vázquez Recused	

Subject Responsible Party Discussion Action Due I (Assigned T	
---	--

B. Licensing	J. Vázquez,	1. Review of Pharmacist Applications:	
Committee	Commissioner	<ul> <li>a. 138207- Requesting to extend her application for three months to take her exams.</li> <li>Committee Recommendation: Deny, the extension and</li> </ul>	
		will need to reapply.	
		2. Review of Pharmacist Renewal Applications:	
		<ul> <li>a. N.N- Requesting to be exempt from the Implicit Bias in place of his teaching scholarship activities in the area.</li> <li>Committee Recommendation: Deny. This is not required by the MD BOP but the state. We will provide you a link to do bias.</li> </ul>	
		<b>b. J.C-</b> Requesting to waive the reinstatement fee. Committee Recommendation: <i>Deny</i> .	
		3. Review of Pharmacist Reinstatement Applications:	
		4. Review of Technician Applications: NONE	
		5. Review of Technician Reinstatement Applications: NONE	
		6. Review of Intern New Applications: NONE	
		7. Review of Pharmacy Applications: NONE	
		<b>a. 141823-</b> Requesting an exemption for FDA, NABP, or State Board of Pharmacy inspection within 90 days. The pharmacy has a Clean Room inspection from 3/6/2024 and a New York State Board of Pharmacy inspection from April 2022. <b>Committee Recommendation:</b> <i>Deny</i>	
		8. Review of Continuing Education Program Request:	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		Magtaring Diabates Davises Integrating Continuous	
		a. Mastering Diabetes Devices Integrating Continuous Glucose Monitors, Insulin Pumps and Automated- Requesting 6.5 Committee Recommendation: Deny, work with the program and NABP to get it recognized.	
		9. Review of Pharmacy Technicians Training Programs:	
		a. University of Maryland Medical Center Pharmacy Technician Training Program Committee Recommendation: Approve	
		b. PEER Pharmacy Technician Training program; EdenRX Pharmacy Committee Recommendation: Approve Commissioner Leikach Recused	
		c. MedSurg Pharmacy using (PEER) <u>Committee Recommendation:</u> Approve  Commissioner Leikach Recused	
		d. Lifeline Glen Burnie Pharmacy Technician Training Program Committee Recommendation: Approve	
		10. New Business: NONE	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
	J		
C. Public Relations Committee	J. Vázquez, Chair	Public Relations Committee Update:	
D. Disciplinary	K. Fink, Chair	Disciplinary Committee Update	
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update	
IV. Other Business & FYI	N. Leikach, President		
V. Adjournment	N. Leikach, President	<ul> <li>A. The Public Meeting was adjourned</li> <li>B. I would like to ask for a motion to close the public meeting and open a closed public session for the purpose of engaging in medical review committee deliberations of confidential matters contained in licensure applications in accordance with General Provisions Article Section 3-305(b)(13).</li> <li>C. Immediately thereafter, N. Leikach, convened an Administrative Session for purposes of discussing confidential disciplinary cases.</li> <li>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to</li> </ul>	

participate in the Administrative Session.